Skip to main content
. Author manuscript; available in PMC: 2018 Apr 27.
Published in final edited form as: Sci Transl Med. 2017 May 24;9(391):eaal4682. doi: 10.1126/scitranslmed.aal4682

Fig. 6. Therapeutic targeting of HER3 sensitizes HER2-amplified BC BMs to HER2 inhibition.

Fig. 6

Tumor growth curve (A and B) and survival analysis (C and D) of established BT474-Gluc brain tumors untreated or treated with trastuzumab, neratinib, pertuzumab, LJM716, and indicated combinations (n = 8 to 10 per group; log-rank test; trastuzumab + LJM716 versus trastuzumab: HR, 0.16, 95% CI, 0.03 to 0.83; **P < 0.001; trastuzumab + pertuzumab versus trastuzumab: HR, 0.17; 95% CI, 0.04 to 0.85; **P < 0.001; neratinib + LJM716 versus neratinib: HR, 0.24; 95% CI, 0.06 to 0.90; P < 0.001; neratinib + pertuzumab versus neratinib: HR, 0.24; 95% CI, 0.06 to 0.91; P = 0.001). Tumor size data are means ± SD. IgG, immunoglobulin G. (E) Representative bioluminescence whole-body imaging of brain BT474-Gluc tumors from an intracarotid model. Tumor growth curve (F) and survival analysis (G) of BT474-Gluc brain tumors treated with trastuzumab (n = 13) or trastuzumab + LJM716 (n = 8) in the intracarotid model (log-rank test: HR, 0.30; 95% CI, 0.11 to 0.83; *P = 0.02).